Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
On March 5, 2026, the FDA approved the combination of Daratumumab + Hyaluronidase-fihji + Teclistamab for use in adult patients with relapsed or refractory multiple myeloma. Additionally, the FDA notice announced the conversion of teclistamab monotherapy from accelerated to traditional approval. This change applies to adults with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy (1)
(1) [fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-combination-daratumumab-hyaluroni…